A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
argenx
Summary
This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efgartigimod at enrolment will be eligible to enroll into the efgartigimod cohort. Patients with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment will be eligible to enroll into the non-efgartigimod cohort.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Patients diagnosed with gMG who are expected to start commercial efgartigimod at enrolment or who are within their first cycle of efgartigimod at enrolment or Patients diagnosed with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment * Have provided appropriate written informed consent Exclusion Criteria: * None
Interventions
- Biologicalefgartigimod
efgartigimod
Locations (35)
- UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center - Brain Tumor Center,San Francisco, California
- SFM Clinical Research, LLCBoca Raton, Florida
- University of Florida College of Medicine JacksonvilleJacksonville Beach, Florida
- Medsol Clinical Research Center IncPort Charlotte, Florida
- BayCare Health System, Inc. St Anthony's HospitalSt. Petersburg, Florida
- Prairie Education and Research Cooperative and HSHS Medical GroupO'Fallon, Illinois